Literature DB >> 33733693

Radiomics on radiography predicts giant cell tumor histologic response to denosumab.

Yu-Cherng Chang1, Radka Stoyanova2,3, Sofia Danilova4, Juan A Pretell-Mazzini3,5, Darcy A Kerr6,7, Breelyn A Wilky8, Ty Subhawong9,10.   

Abstract

OBJECTIVE: Denosumab is an established targeted systemic therapy for treatment of giant cell tumor of bone (GCTB). We sought to determine whether treatment response could be quantified from radiomics analysis of radiographs taken longitudinally during treatment.
MATERIALS AND METHODS: Pre- and post-treatment radiographs of 10 GCTB tumors from 10 patients demonstrating histologic response after treatment with denosumab were analyzed. Intensity- and texture-based radiomics features for each manually segmented tumor were calculated. Radiomics features were compared pre- and post-treatment in tumors.
RESULTS: Mean intensity (p = 0.033) significantly increased while skewness (p = 0.028) significantly decreased after treatment. Post-treatment increases in fractal dimensions (p = 0.057) and abundance (p = 0.065) approached significance. A potential linear correlation in mean (p = 0.005; ΔMean = 0.022 * duration - 0.026) with treatment duration was observed.
CONCLUSION: Radiomics analysis of plain radiographs quantifies time-dependent matrix mineralization and trabecular reconstitution that mark positive response of giant cell tumors of bone to denosumab.
© 2021. ISS.

Entities:  

Keywords:  Denosumab; Giant cell tumor; Radiograph; Radiomics; Treatment response

Year:  2021        PMID: 33733693     DOI: 10.1007/s00256-021-03752-5

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  1 in total

Review 1.  State of the Art and New Concepts in Giant Cell Tumor of Bone: Imaging Features and Tumor Characteristics.

Authors:  Anna Parmeggiani; Marco Miceli; Costantino Errani; Giancarlo Facchini
Journal:  Cancers (Basel)       Date:  2021-12-15       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.